Skip to main content

Principal Associate Scientist, Biology

Parabilis Medicines · Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

$108K–$128KCambridge101-250 employeesPosted 25 days ago
Post-IPO Equity · $75Mraised 5 months agoled by General Catalyst, RA Capital Management, ARCH Venture Partners

This board only lists companies whose most recent round closed in the last 180 days.

Apply on Parabilis Medicines’s site
<p style="text-align: left;">&nbsp;</p> <p><strong><span data-contrast="auto">About&nbsp;Parabilis&nbsp;Medicines</span></strong><span data-ccp-props="{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559685&quot;:0,&quot;335559737&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:259}">&nbsp;</span></p> <p><span data-contrast="none">Parabilis&nbsp;Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long&nbsp;considered undruggable.&nbsp;The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational&nbsp;medicine,&nbsp;zolucatetide, is the first and only direct inhibitor&nbsp;of the&nbsp;β-catenin:TCF&nbsp;interaction,&nbsp;a central node in the&nbsp;Wnt/β-catenin pathway that has&nbsp;eluded drug developers&nbsp;for decades.&nbsp;Zolucatetide&nbsp;is being evaluated in the clinic across multiple&nbsp;Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP)&nbsp;and&nbsp;a range&nbsp;of&nbsp;other&nbsp;solid tumor indications. Beyond&nbsp;zolucatetide,&nbsp;Parabilis&nbsp;is advancing additional&nbsp;Helicon-based&nbsp;programs focused on other challenging targets&nbsp;where we believe&nbsp;our&nbsp;medicines could have life-altering impact. For more information, visit </span><a href="https://url.us.m.mimecastprotect.com/s/gYX5CkRVZgtkknDEuVhmcGHXzh?domain=parabilismed.com/"><span data-contrast="none"><span data-ccp-charstyle="Hyperlink">www.parabilismed.com</span></span></a><span data-contrast="none">&nbsp;or follow us on&nbsp;</span><a href="https://url.us.m.mimecastprotect.com/s/7qd3ClYV50H11oWrFyinczUQak?domain=linkedin.com"><span data-contrast="none"><span data-ccp-charstyle="Hyperlink">LinkedIn</span></span></a><span data-contrast="none">.</span><span data-ccp-props="{&quot;335551550&quot;:6,&quot;335551620&quot;:6}">&nbsp;</span></p> <p><strong>What’s the opportunity?</strong></p> <p>We are seeking a highly motivated, hands-on Principal Associate Scientist to join our Biology team and support the advancement of pre-clinical oncology programs. This scientist will be a key bench-facing member of the program, designing and executing the cellular and molecular experiments to understand how Helicon candidates engage and interfere with the target; how target interference alters cancer-cell biology, and which pharmacodynamic and response biomarkers may help translate the mechanism toward development.</p> <p>The successful candidate will generate rigorous, decision-enabling data and provide scientifically grounded recommendations to help define translational and clinical opportunities for addressing significant unmet medical needs.</p> <p>Reporting to the program biology lead, the ideal candidate combines excellent experimental skills with strong mechanistic reasoning. This individual will work independently on problems of diverse scope, develop and qualify new assays, adapt published approaches to novel scientific questions, and generate high-impact biology data in a highly collaborative, fast-paced biotechnology environment.</p> <p>Key Responsibilities</p> <ul> <li>Independently design, optimize, execute, and troubleshoot cell-based assays to characterize and assess lead Helicons, including target engagement, potency, selectivity, mechanism of action, and differentiation opportunities.</li> <li>Develop and apply cellular and molecular assays, including CETSA, AlphaLISA, HTRF, NanoBRET, cell proliferation, qPCR, ELISA/MSD, Co-IP, flow cytometry, and western blot across 2D and 3D cell models.</li> <li>Develop, optimize, and qualify new assay systems and disease-relevant models—including cancer cell lines, primary cells, and 3D organoid cultures—to address questions that existing platforms cannot answer.</li> <li>Investigate the biological contexts associated with sensitivity and resistance to lead Helicons and develop testable hypotheses for pharmacodynamic and response biomarkers.</li> <li>Work with Translational Biology, DMPK and in vivo Pharmacology colleagues to select informative models and translate cellular findings into tissue PK/PD and biomarker studies where appropriate.</li> <li>Collaborate closely with other functions within the program to generate decision-enabling biology data supporting lead optimization, development-candidate nomination and IND-enabling activities.</li> <li>Present experimental results, interpretations, and recommendations clearly to project teams, the broader Biology and company organizations.</li> <li>Maintain complete, timely and traceable experimental records and uphold high standards for data integrity, reproducibility and scientific transparency.</li> </ul> <p><strong>What you’ll need to be successful:</strong></p> <ul> <li>B.S. in cell biology, molecular biology, cancer biology or a related field with 8+ years of industry experience in biotechnology or pharmaceuticals, or an M.S. with 6+ years.</li> <li>Substantial hands-on experience with mammalian cell biology, cell culture and quantitative cell-based pharmacology or assay development.</li> <li>Demonstrated proficiency in cell and molecular biology techniques such as HTRF, AlphaLISA, CETSA, Western, Co-IP, qPCR, CyQUANT, Flow Cytometry, ELISA/MSD, Imaging, etc.</li> <li>Experience using CRISPR/Cas9, RNAi, viral expression/transduction, or related genetic approaches to investigate biological mechanisms.</li> <li>Experience studying determinants of drug response or resistance and developing pharmacodynamic or response-biomarker hypotheses is highly desirable.</li> <li>Demonstrated ability to adapt published methods to novel scientific questions and to build working relationships with collaborators outside your own area of expertise.</li> <li>Experience in oncology drug discovery is strongly preferred. Familiarity with peptides, targeted protein degradation, or other therapeutic modalities beyond conventional small molecules is a plus.</li> <li>Strong organizational skills and meticulous attention to detail in experimental documentation.</li> <li>Collaborative mindset with a high degree of initiative, curiosity, and enthusiasm for developing revolutionary medicines.</li> </ul> <p><strong>Core Values</strong></p> <p>Parabilis Medicines is a team of passionate pioneers who are trailblazing the future of precision medicine with the aim of making a meaningful difference in the lives of patients. The company is committed to promoting an inspiring and flourishing working environment for all employees across the business, in all departments, and driving innovation for patient benefit.</p> <ul> <li><strong>Growth-Minded</strong>. We’re inventing a new class of medicines—one applicable to therapeutic targets that have been dreamt about, but always considered impossible to drug. Our work requires us to be curious, humble and adaptable.</li> <li><strong>In(ter)dependent.</strong> We are fiercely&nbsp;<em>independent</em>&nbsp;as a leader in&nbsp;defying the limitations of current therapeutic modalities, and&nbsp;<em>interdependent</em> as a team as we&nbsp;work collaboratively to shift&nbsp;drug discovery paradigms and provide patients with better treatment options.</li> <li><strong>Patient-focused. </strong>We are deeply focused on patient outcomes, and all energy in the company is focused on science as it translates to patient impact.</li> <li><strong>All-In. </strong>We’re All-In on solving some of the hardest scientific challenges and delivering one of the most effective new classes of drugs in history.</li> </ul> <p><span style="font-weight: 400;">The base salary range for this position is $108,000-$128,000, depending on experience, qualifications, and internal practices. Parabilis’s total compensation package also includes an annual target bonus, equity, and a comprehensive suite of competitive<strong> </strong>benefits designed to support our employees’ overall well-being.</span></p> <p><span style="font-weight: 400;">As an equal opportunity employer, Parabilis Medicines values an inclusive workplace and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.</span></p> <p><span style="font-weight: 400;"><span style="font-weight: 300;">30 Acorn Park Drive&nbsp; &nbsp; |&nbsp; &nbsp; &nbsp;Cambridge, MA 02140&nbsp; &nbsp; |&nbsp; &nbsp; www.parabilismed.com</span></span></p>
Apply on Parabilis Medicines’s site

Applications go straight to the employer. VCBacked does not sit between you and the company.

993 more roles posted in the last 48 hours

You are seeing the board after its 48-hour member window. Job Seeker opens that window and sends an alert the moment a role hits — applicants in the first 24 hours land 90 percent of interviews.

Looking for more roles like this? JustBacked lists every open job at startups that raised in the last six months.

Back to all roles at freshly funded companies